Prothena (PRTA)
(Delayed Data from NSDQ)
$20.87 USD
+0.31 (1.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $20.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 301 - 320 ( 329 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Amyloidosis Data H1:14 - Weakness Around Elan/Perrigo Selling an Opportunity to Buy
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Amyloidosis Data H1:14 - Weakness Around Elan/Perrigo Selling an Opportunity to Buy - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Roche Climbs Aboard the Synuclein Train; Target to $36
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Increasing Price Target to $45 from $32 - Roche Partnership for Targeted Parkinson''s and Synucleinopathies Antibody Therapy Impressive
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Q3 Update - NEO001 Amyloidosis Data and PRX002, a Targeted Antibody for Parkinson''s, to Drive Value in 2014
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
ASH 2013 Abstracts Highlight High Unmet Medical Need in AL Amyloidosis - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
ASH 2013 Abstracts Highlight High Unmet Medical Need in AL Amyloidosis - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Analyst Day Takeaways: Significant Opportunity in Next Two Clinical Candidates Overlooked - Next Up, NEOD001 Data in Amyloidosis H1:14
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Analyst Day Takeaways: Significant Opportunity in Next Two Clinical Candidates Overlooked - Next Up,
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Increasing Price Target to $32 - Nov. 4 Analyst Day to Highlight Clinical Path Forward in Amyloidosis
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.